An observational study in Carcinoma, Hepatocellular, sponsored by Eisai Inc.. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Eisai Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Carcinoma, Hepatocellular by Eisai Co., Ltd. — none open to participants now, 4 under way, none of them phase 3. Carcinoma, Hepatocellular · Eisai Co., Ltd..
Among the 20 studies in Carcinoma, Hepatocellular by Eisai Co., Ltd., this one is the only one that started in 2025, is one of 6 observational ones, and was the 20th registered.
3,653 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,065 are open to participants now.
Browse Carcinoma, Hepatocellular studies →None of the 20 studies in Carcinoma, Hepatocellular by Eisai Co., Ltd. is open now. The open studies under Carcinoma, Hepatocellular, anywhere →
Of the 741 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 251 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 6 · Phase 3 2 · Phase 4 1
First in 2004; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 170 is below the median of 200 across 852 observational studies indexed under Carcinoma, Hepatocellular.
Median enrollment 80 across the 14 interventional studies, 374 across the 6 observational. Of the 16 that completed or were terminated, 8 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
4 of the studies in Carcinoma, Hepatocellular by Eisai Co., Ltd. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07849660Eisai Inc.Real-World Lenvatinib Sequencing in Unresectable Hepatocellular Carcinoma (uHCC) | 2026-12-15 |
| NCT03833700Eisai Co., Ltd.A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC) | 2027-03-31 |
| NCT04008797Eisai Inc.A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | 2027-03-31 |
| NCT03264664Eisai Inc.Study of E7386 in Participants With Selected Advanced Neoplasms | 2027-03-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 20 studies in Carcinoma, Hepatocellular by Eisai Co., Ltd., from their registry updates:
This tab as a report to print or save as PDF → With an account.
This observational study will use existing real-world data from routine clinical care to describe patients with uHCC who received lenvatinib. The study will include two groups: patients who started lenvatinib as first-line (1L) treatment and patients who started lenvatinib as second-line (2L) treatment after prior 1L immunotherapy was stopped because the cancer progressed or because of toxicity. All study information will be collected retrospectively from existing patient records. Patients will be followed from the start of lenvatinib until death or their last documented follow-up before data extraction.
The primary objectives of this study are:
To retrospectively evaluate the effectiveness of 2L lenvatinib as measured by OS after progression on or discontinuation of prior 1L immunotherapy
Patients in both Cohorts must be adults with uHCC not amenable to locoregional therapy (LRT), diagnosed from 01 Sept 2020 to 30 Sept 2023, and confirmed by radiology, histology, or cytology. They will be excluded for main portal vein invasion (Vp4), esophageal or gastric variceal bleeding within 6 months before the index date, concurrent malignancy requiring active treatment (except non-melanoma skin cancer or curatively treated in situ cervical cancer), or prior liver transplant.
Cohort A patients must have started 1L lenvatinib at the FDA-approved dose and have BCLC Stage B/C disease, ECOG performance status 0/1, and Child-Pugh A (score 5/6) liver function.
Cohort B patients must have received 1L atezolizumab plus bevacizumab or durvalumab plus tremelimumab, then progressed or discontinued due to toxicity, with BCLC Stage B/C disease, ECOG performance status 0/1, and Child-Pugh A (score 5/6) or B (score 7) liver function.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosed with uHCC, as confirmed by radiology, histology, or cytology
Cohort A
Cohort B
Exclusion Criteria:
Cohort A
Cohort B
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Lenvatinib
Drug: Lenvatinib
12 milligram (mg) based on the participant's body weight greater than or equal to (≥) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (\<) 60 kg at baseline, orally, once daily (QD)
Also known as: Lenvima
Cohort A Overall Survival (OS)
Retrospectively evaluate the effectiveness of 1L Lenvatinib in a real-world setting
Time frame: From initiation of Lenvatinib therapy until date of death or until last available follow-up before data extraction (approximately 2 years)
Cohort B OS
Retrospectively evaluate the effectiveness of 2L Lenvatinib
Time frame: From initiation of Lenvatinib therapy until date of death or until last available follow-up before data extraction (approximately 2 years)
Best Clinical Response to Lenvatinib Therapy
Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD)
Time frame: From initiation of Lenvatinib therapy until date of death or until last available follow-up before data extraction (approximately 2 years)
Overall Response Rate (ORR)
Proportion of patients with a best response to Lenvatinib therapy of CR or PR
Time frame: From initiation of Lenvatinib therapy until date of death or until last available follow-up before data extraction (approximately 2 years)
Disease Control Rate (DCR)
Proportion of patients with a best response to Lenvatinib therapy of CR, PR, or SD
Time frame: From initiation of Lenvatinib therapy until date of death or until last available follow-up before data extraction (approximately 2 years)
Clinical Benefit Rate (CBR)
Proportion of patients with a best response to Lenvatinib therapy of CR, PR, or durable SD (duration of stable disease ≥23 weeks)
Time frame: From initiation of Lenvatinib therapy until date of death or until last available follow-up before data extraction (approximately 2 years)
Progression Free Survival (PFS)
Time from the date of Lenvatinib initiation until the date of first documented progression or death (whichever occurs first)
Time frame: From initiation of Lenvatinib therapy until date of death or until last available follow-up before data extraction (approximately 2 years)
Progression Free Survival Post-Progression (PFS2)
Time from the date of Lenvatinib initiation until the date of disease progression on the next-line treatment or death from any cause (whichever occurs first)
Time frame: From initiation of Lenvatinib therapy until date of death or until last available follow-up before data extraction (approximately 2 years)
Time to Next Treatment (TTNT) from Lenvatinib Initiation
Time from the date of Lenvatinib initiation until the date of start of next treatment
Time frame: From initiation of Lenvatinib therapy until date of death or until last available follow-up before data extraction (approximately 2 years)
Treatment Patterns in uHCC Patients that received Lenvatinib
Treatment patterns will include time to Lenvatinib discontinuation, duration of Lenvatinib treatment, Lenvatinib dose intensity, reasons for Lenvatinib discontinuation, percentage with and time to first Lenvatinib dose reduction, and proportion with and time to surgical resection and transplantation after Lenvatinib initiation
Time frame: From initiation of Lenvatinib therapy until date of death or until last available follow-up before data extraction (approximately 2 years)
Relational Sequencing of All Treatment Regimens received for uHCC
Relational sequencing will include 1L and 2L Lenvatinib, 1L immunotherapy (for Cohort B), and all subsequent treatment lines after Lenvatinib discontinuation
Time frame: From initiation of Lenvatinib therapy until date of death or until last available follow-up before data extraction (approximately 2 years)
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.